We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for imlifidase (Hansa Biopharma (Australia) Pty Ltd)
Active ingredients
imlifidase
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for concentrate for solution for infusion
Indication
Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney patients with a positive cross match against an available donor prior to kidney transplantation. The use of Idefirix should be reserved for patients who are unlikely to be otherwise transplanted.
Therapeutic area
Immunology